Hemostatic Matrix Industry Insights: Demand & Innovation
Hemostatic Matrix Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):–
The Global Hemostatic Matrix Market reached US$ 2.92 billion in 2023 and is expected to reach US$ 4.70 billion by 2031, growing at a CAGR of 6.2% during the forecast period 2024-2031.
List of the Key Players in the Hemostatic Matrix Market:
Pfizer Inc., Ethicon (Johnson & Johnson), Baxter International Inc., Becton, Dickinson and Company (BD), B. Braun SE, Integra LifeSciences Corporation., CryoLife, Inc. (Artivion, Inc), Advanced Medical Solutions Group plc, Aegis Lifesciences, and Teleflex Incorporated. among others.
Industry Development:
August 2023: Teleflex Incorporated secured FDA clearance for its QuikClot Control+ Hemostatic Device, expanding its indications to include mild and moderate bleeding management in cardiac surgeries and bone surface bleeding post-sternotomy. This approval enhances its role in comprehensive bleeding control during cardiac procedures.
July 2023: Baxter International Inc. introduced PERCLOT Absorbable Hemostatic Powder in the U.S., adding to its portfolio of surgical innovations. Designed for patients with intact coagulation systems, PERCLOT is a passive, absorbable hemostatic agent aimed at managing mild bleeding during surgeries.
March 2023: Bengaluru-based med-tech firm Axio Biosolutions received FDA 510(k) clearance for its Ax-Surgi Surgical Hemostat, making it the first chitosan-based hemostatic agent approved for controlling severe surgical bleeding—marking a major milestone in surgical hemostasis.
Growth Forecast Projected:
The Global Hemostatic Matrix Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Both primary and secondary data sources have been used in the global Hemostatic Matrix Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Segment Covered in the Hemostatic Matrix Market:
By Product Type: Gelatin-based Hemostatic Matrix, Collagen-based Hemostatic Matrix, Thrombin-based Hemostatic Matrix, Combination Hemostatic Matrix
By Form: Gel, Foam, Powder, Paste
By Application: Surgical ProceduresCardiovascular Surgery, Orthopedic Surgery, Neurosurgery, General Surgery, Gynecological Surgery, Urology Surgery, Others, Trauma Care, Wound Care
By End-User: Hospitals, Ambulatory Surgical Centers, Trauma Centers, Specialty Clinics
By Distribution Channel: Direct Sales, Medical Supply Distributors, Online Sales
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian